JAK2-IN-14

• Description:

  JAK2-IN-14 is an orally active JAK2 inhibitor with an IC50 of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) [1].

• UNSPSC:

  12352100

• Target:

  Apoptosis; JAK; STAT

• Related Pathways:

  Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  CC1=CN=C(NC2=CC=C(N3CCN(CC4CC4)CC3)C5=C2)N=C1C6=CN(CCCCO5)N=C6

• Molecular Formula:

  C26H33N7O

• Molecular Weight:

  459.59

• References & Citations:

  [1]Qin S, et al. Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs. J Med Chem. 2025 Aug 28;68 (16) :17933-17959.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  JAK1; JAK2; JAK3; STAT5; Tyk2

• CAS Number:

  3087335-24-5